The Spectrum of Renal Allograft Failure.

BACKGROUND:Causes of "true" late kidney allograft failure remain unclear as study selection bias and limited follow-up risk incomplete representation of the spectrum. METHODS:We evaluated all unselected graft failures from 2008-2014 (n = 171; 0-36 years post-transplantation) by contemporar...

Full description

Bibliographic Details
Main Authors: Sourabh Chand, David Atkinson, Clare Collins, David Briggs, Simon Ball, Adnan Sharif, Kassiani Skordilis, Bindu Vydianath, Desley Neil, Richard Borrows
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5029903?pdf=render
id doaj-246ed5c2f13b48e2a3876c34a593fad9
record_format Article
spelling doaj-246ed5c2f13b48e2a3876c34a593fad92020-11-25T02:13:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01119e016227810.1371/journal.pone.0162278The Spectrum of Renal Allograft Failure.Sourabh ChandDavid AtkinsonClare CollinsDavid BriggsSimon BallAdnan SharifKassiani SkordilisBindu VydianathDesley NeilRichard BorrowsBACKGROUND:Causes of "true" late kidney allograft failure remain unclear as study selection bias and limited follow-up risk incomplete representation of the spectrum. METHODS:We evaluated all unselected graft failures from 2008-2014 (n = 171; 0-36 years post-transplantation) by contemporary classification of indication biopsies "proximate" to failure, DSA assessment, clinical and biochemical data. RESULTS:The spectrum of graft failure changed markedly depending on the timing of allograft failure. Failures within the first year were most commonly attributed to technical failure, acute rejection (with T-cell mediated rejection [TCMR] dominating antibody-mediated rejection [ABMR]). Failures beyond a year were increasingly dominated by ABMR and 'interstitial fibrosis with tubular atrophy' without rejection, infection or recurrent disease ("IFTA"). Cases of IFTA associated with inflammation in non-scarred areas (compared with no inflammation or inflammation solely within scarred regions) were more commonly associated with episodes of prior rejection, late rejection and nonadherence, pointing to an alloimmune aetiology. Nonadherence and late rejection were common in ABMR and TCMR, particularly Acute Active ABMR. Acute Active ABMR and nonadherence were associated with younger age, faster functional decline, and less hyalinosis on biopsy. Chronic and Chronic Active ABMR were more commonly associated with Class II DSA. C1q-binding DSA, detected in 33% of ABMR episodes, were associated with shorter time to graft failure. Most non-biopsied patients were DSA-negative (16/21; 76.1%). Finally, twelve losses to recurrent disease were seen (16%). CONCLUSION:This data from an unselected population identifies IFTA alongside ABMR as a very important cause of true late graft failure, with nonadherence-associated TCMR as a phenomenon in some patients. It highlights clinical and immunological characteristics of ABMR subgroups, and should inform clinical practice and individualised patient care.http://europepmc.org/articles/PMC5029903?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Sourabh Chand
David Atkinson
Clare Collins
David Briggs
Simon Ball
Adnan Sharif
Kassiani Skordilis
Bindu Vydianath
Desley Neil
Richard Borrows
spellingShingle Sourabh Chand
David Atkinson
Clare Collins
David Briggs
Simon Ball
Adnan Sharif
Kassiani Skordilis
Bindu Vydianath
Desley Neil
Richard Borrows
The Spectrum of Renal Allograft Failure.
PLoS ONE
author_facet Sourabh Chand
David Atkinson
Clare Collins
David Briggs
Simon Ball
Adnan Sharif
Kassiani Skordilis
Bindu Vydianath
Desley Neil
Richard Borrows
author_sort Sourabh Chand
title The Spectrum of Renal Allograft Failure.
title_short The Spectrum of Renal Allograft Failure.
title_full The Spectrum of Renal Allograft Failure.
title_fullStr The Spectrum of Renal Allograft Failure.
title_full_unstemmed The Spectrum of Renal Allograft Failure.
title_sort spectrum of renal allograft failure.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description BACKGROUND:Causes of "true" late kidney allograft failure remain unclear as study selection bias and limited follow-up risk incomplete representation of the spectrum. METHODS:We evaluated all unselected graft failures from 2008-2014 (n = 171; 0-36 years post-transplantation) by contemporary classification of indication biopsies "proximate" to failure, DSA assessment, clinical and biochemical data. RESULTS:The spectrum of graft failure changed markedly depending on the timing of allograft failure. Failures within the first year were most commonly attributed to technical failure, acute rejection (with T-cell mediated rejection [TCMR] dominating antibody-mediated rejection [ABMR]). Failures beyond a year were increasingly dominated by ABMR and 'interstitial fibrosis with tubular atrophy' without rejection, infection or recurrent disease ("IFTA"). Cases of IFTA associated with inflammation in non-scarred areas (compared with no inflammation or inflammation solely within scarred regions) were more commonly associated with episodes of prior rejection, late rejection and nonadherence, pointing to an alloimmune aetiology. Nonadherence and late rejection were common in ABMR and TCMR, particularly Acute Active ABMR. Acute Active ABMR and nonadherence were associated with younger age, faster functional decline, and less hyalinosis on biopsy. Chronic and Chronic Active ABMR were more commonly associated with Class II DSA. C1q-binding DSA, detected in 33% of ABMR episodes, were associated with shorter time to graft failure. Most non-biopsied patients were DSA-negative (16/21; 76.1%). Finally, twelve losses to recurrent disease were seen (16%). CONCLUSION:This data from an unselected population identifies IFTA alongside ABMR as a very important cause of true late graft failure, with nonadherence-associated TCMR as a phenomenon in some patients. It highlights clinical and immunological characteristics of ABMR subgroups, and should inform clinical practice and individualised patient care.
url http://europepmc.org/articles/PMC5029903?pdf=render
work_keys_str_mv AT sourabhchand thespectrumofrenalallograftfailure
AT davidatkinson thespectrumofrenalallograftfailure
AT clarecollins thespectrumofrenalallograftfailure
AT davidbriggs thespectrumofrenalallograftfailure
AT simonball thespectrumofrenalallograftfailure
AT adnansharif thespectrumofrenalallograftfailure
AT kassianiskordilis thespectrumofrenalallograftfailure
AT binduvydianath thespectrumofrenalallograftfailure
AT desleyneil thespectrumofrenalallograftfailure
AT richardborrows thespectrumofrenalallograftfailure
AT sourabhchand spectrumofrenalallograftfailure
AT davidatkinson spectrumofrenalallograftfailure
AT clarecollins spectrumofrenalallograftfailure
AT davidbriggs spectrumofrenalallograftfailure
AT simonball spectrumofrenalallograftfailure
AT adnansharif spectrumofrenalallograftfailure
AT kassianiskordilis spectrumofrenalallograftfailure
AT binduvydianath spectrumofrenalallograftfailure
AT desleyneil spectrumofrenalallograftfailure
AT richardborrows spectrumofrenalallograftfailure
_version_ 1724904858133200896